|
🐬
|
Incidence and risk factors for venous thromboembolism in critically ill children after trauma.
S. Hanson,
R. Punzalan,
R. Greenup,
Hua Liu,
Thomas T. Sato,
P. Havens
|
6 |
2010 |
6
🐬
|
|
🐜
|
Effectiveness of clinical guidelines for deep vein thrombosis prophylaxis in reducing the incidence of venous thromboembolism in critically ill children after trauma
9 auth.
S. Hanson,
R. Punzalan,
M. Arca,
P. Simpson,
M. Christensen,
Sydney K. Hanson,
...
K. Yan,
Kristin Braun,
P. Havens
|
6 |
2012 |
6
🐜
|
|
🦁
|
Low-molecular-weight heparin in thrombotic disease in children and adolescents.
R. Punzalan,
C. Hillery,
R. Montgomery,
J. Scott,
J. Gill
|
6 |
2000 |
6
🦁
|
|
🐬
|
Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation*
R. Niebler,
R. Punzalan,
M. Marchan,
M. Lankiewicz
|
5 |
2010 |
5
🐬
|
|
🐜
|
Erythrocyte adhesion is modified by alterations in cellular tonicity and volume
9 auth.
N. Wandersee,
R. Punzalan,
M. Rettig,
M. Kennedy,
N. Pajewski,
R. Sabina,
...
J. Paul Scott,
P. Low,
C. Hillery
|
5 |
2005 |
5
🐜
|
|
🐬
|
Incidence and Risk Factors for Venous Thromboembolism in Critically Ill Children With Cardiac Disease
S. Hanson,
R. Punzalan,
M. Christensen,
N. Ghanayem,
E. Kuhn,
P. Havens
|
5 |
2011 |
5
🐬
|
|
🐜
|
Higher Doses of Low-Molecular-Weight Heparin (Enoxaparin) Are Needed to Achieve Target Anti-Xa Concentrations in Critically Ill Children*
7 auth.
Nathan J. Schloemer,
S. Abu-Sultaneh,
S. Hanson,
K. Yan,
R. Hoffmann,
R. Punzalan,
...
P. Havens
|
4 |
2014 |
4
🐜
|
|
🐬
|
The use of novel Therakos™ Cellex® for extracorporeal photopheresis in treatment of graft‐versus‐host disease in paediatric patients
H. Rangarajan,
R. Punzalan,
B. Camitta,
J. Talano
|
4 |
2013 |
4
🐬
|
